was read the article
array:25 [ "pii" => "S1578219021002584" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.09.007" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2671" "copyright" => "AEDV" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:939-41" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731021001939" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.05.011" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2671" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:939-41" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Erupción fototóxica inducida por leflunomida en una paciente con lupus eritematoso sistémico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "939" "paginaFinal" => "941" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Leflunomide-Induced Phototoxic Reaction in a Woman With Systemic Lupus Erythematosus" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1711 "Ancho" => 758 "Tamanyo" => 186474 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A) Erupción máculo-papular eritematoviolácea en tronco anterior y cuello. B) Erupción máculo-papular eritematoviolácea en tronco posterior con formaciones ampollosas aisladas. C) Evolución a las 48 h del inicio de la erupción con formación de ampollas.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "F.J. Navarro-Triviño, N. Lucas-Collado, J. Salvatierra-Ossorio" "autores" => array:3 [ 0 => array:2 [ "nombre" => "F.J." "apellidos" => "Navarro-Triviño" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Lucas-Collado" ] 2 => array:2 [ "nombre" => "J." "apellidos" => "Salvatierra-Ossorio" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219021002584" "doi" => "10.1016/j.adengl.2021.09.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002584?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001939?idApp=UINPBA000044" "url" => "/00017310/0000011200000010/v1_202111020534/S0001731021001939/v1_202111020534/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219021002742" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.10.006" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2663" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:941-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Mitotic Rate as a Prognostic Factor in Melanoma: Implications for Disease Management" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "941" "paginaFinal" => "943" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "El índice mitótico como factor pronóstico y sus implicancias en el manejo del melanoma" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.C. Bois, D. Morgado-Carrasco, P.J. Barba, S. Puig" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M.C." "apellidos" => "Bois" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 2 => array:2 [ "nombre" => "P.J." "apellidos" => "Barba" ] 3 => array:2 [ "nombre" => "S." "apellidos" => "Puig" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731021001812" "doi" => "10.1016/j.ad.2020.05.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001812?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002742?idApp=UINPBA000044" "url" => "/15782190/0000011200000010/v1_202111080506/S1578219021002742/v1_202111080506/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S1578219021002602" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.09.009" "estado" => "S300" "fechaPublicacion" => "2021-11-01" "aid" => "2655" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:936-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Hidradenitis Suppurativa Treated With Apremilast: A Case Series" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "936" "paginaFinal" => "939" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hidradenitis supurativa tratada con apremilast: serie de casos" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2565 "Ancho" => 3008 "Tamanyo" => 259048 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical rating scales for hidradenitis suppurativa patients treated with apremilast. Graphs depict the Physician's Global Assessment (PGA), International HS Severity Score System (IHS4), Dermatology Life Quality Index (DLQI), and pain visual analogue scale (VAS, 0–10) scores, expressed as the median and range, at baseline, week 12, and week 24. Statistical analyses were performed to evaluate decreases after 6 months using the Wilcoxon test for paired samples: PGA, <span class="elsevierStyleItalic">P</span> = 0.157; IHS4, <span class="elsevierStyleItalic">P</span> = 0.068; DLQI, <span class="elsevierStyleItalic">P</span> = 0.043; pain VAS, <span class="elsevierStyleItalic">P</span> = 0.042.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Garbayo-Salmons, V. Expósito-Serrano, M. Ribera Pibernat, J. Romaní" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Garbayo-Salmons" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Expósito-Serrano" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Ribera Pibernat" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Romaní" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731021001733" "doi" => "10.1016/j.ad.2020.06.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021001733?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002602?idApp=UINPBA000044" "url" => "/15782190/0000011200000010/v1_202111080506/S1578219021002602/v1_202111080506/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Leflunomide-Induced Phototoxic Reaction in a Woman With Systemic Lupus Erythematosus" "tieneTextoCompleto" => true "saludo" => "To the Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "939" "paginaFinal" => "941" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "F.J. Navarro-Triviño, N. Lucas-Collado, J. Salvatierra-Ossorio" "autores" => array:3 [ 0 => array:4 [ "nombre" => "F.J." "apellidos" => "Navarro-Triviño" "email" => array:1 [ 0 => "fntmed@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "N." "apellidos" => "Lucas-Collado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "J." "apellidos" => "Salvatierra-Ossorio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario San Cecilio, Granada, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario San Cecilio, Granada, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Erupción fototóxica inducida por leflunomida en una paciente con lupus eritematoso sistémico" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1711 "Ancho" => 758 "Tamanyo" => 186474 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A, Erythematous-violaceous maculopapular rash on the anterior trunk and neck. B, Erythematous-violaceous maculopapular rash on the posterior trunk with solitary bullous formations. C, Skin at 48 hours after onset of the rash, with formation of blisters.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Leflunomide is an immunosuppressive agent that has been approved by the United States Food and Drug Administration for the treatment of rheumatoid arthritis and psoriatic arthritis. It is also widely used off-label in other diseases, such as ankylosing spondylitis and systemic lupus erythematosus (SLE). Leflunomide can produce adverse effects, the most common of which are gastrointestinal symptoms, hypertension, and alopecia. Although considered an efficacious and safe drug for the treatment of SLE, leflunomide has been associated with cases of skin rash, such as erythema multiforme<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>, toxic epidermal necrolysis<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a>, and vasculitis<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a>, and it has even triggered skin lesions in subacute lupus erythematosus<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a>.</p><p id="par0010" class="elsevierStylePara elsevierViewall">A 25-year-old woman had been followed by the rheumatology department for a 4-year history of SLE. The diagnostic criteria did not include a history of photosensitivity. Initial treatment was with rituximab (500 mg every 15 days, 2 sessions), oral prednisone in tapering doses, and subcutaneous methotrexate (17.5 mg weekly). Owing to gastrointestinal adverse effects, methotrexate was replaced by leflunomide (3 daily doses of 100 mg followed by a maintenance dose of 20 mg/d) 3 months after initiation. Two months after starting treatment with leflunomide and after intense exposure to sunlight at the beach, the patient came to the clinic with a 24 -h history of very pruritic generalized maculopapular rash (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A-B), which progressed to vesicular-bullous lesions in 48 hours. These mainly affected the arms (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>C) and were associated with pustules on the forehead (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>A), vesicles on the area of the lips (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>B), and ecchymotic macules and papules on both axillae (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>C). Examination of the oral and genital mucosa was normal. The laboratory workup revealed high titers for antinuclear antibodies (1/640 U/mL), anti-Ro/SSA-60 (157), anti-Ro/SSA-52 (167), and rheumatoid factor (80 U/mL). Values for the remaining parameters, including C3 and C4, were normal. Serology testing (herpes simplex virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6) yielded negative results. Histopathology of a punch biopsy specimen from a bullous lesion on the posterior trunk revealed an atrophied epidermis with foci of necrotic keratinocytes and spongiosis, together with a subepidermal bullous formation and a moderate inflammatory perivascular mononuclear infiltrate of lymphocytes and eosinophils in the dermis that was compatible with phototoxic rash. Direct immunofluorescence was negative. Treatment with leflunomide was interrupted, and systemic treatment with oral prednisone (1 mg/kg/d) was started. The lesions had resolved completely after 10 days except for some residual hyperpigmentation.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Patients with SLE are particularly sensitive to sunlight, which is considered a trigger or aggravating factor of the disease. It is rare for a diagnosis of SLE not to include photosensitivity as a criterion. Of the various treatments used in SLE, leflunomide is not a first choice; therefore, it is used in selected patients who experience adverse effects associated with other drugs, such as methotrexate. The literature contains many articles that consider leflunomide as the sole cause of subacute cutaneous lupus erythematosus (SCLE)<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>, as well as SCLE associated with erythema multiforme–type lesions and erythema multiforme major. Some authors are in favor of diagnosing the co-occurrence of lupus erythematosus and erythema multiforme in the same patient as Rowell syndrome, although this is considered controversial. In fact, in the year 2000, Zeitouni et al.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> defined new criteria for the diagnosis of Rowell syndrome. While the patient in the case we report fulfilled sufficient criteria to be diagnosed with this syndrome, our main suspicion was leflunomide-induced phototoxic reaction. Two months after the clinical picture had resolved, the patient underwent patch testing with the European photopatch series (Chemotechnique Diagnostics) and leflunomide 1%, 5%, and 10% in petrolatum, with UV-A radiation at 10 J/cm<span class="elsevierStyleSup">2</span>. The reading was negative at 3 minutes and at 48 and 96 hours.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Photosensitive rash is common in patients with SLE and is included in the diagnostic criteria. However, in the present case, we think that some of the drugs used in this disease could play a relevant role in triggering a phototoxic or photoallergic reaction. Differentiating clinically between phototoxic rash and photosensitive rash in SLE can prove difficult. Histopathology makes it possible to distinguish patients with true SLE, in which immunofluorescence reveals deposits of immunoglobulin M and C3 at the dermal-epidermal junction, findings that are absent in phototoxic rash. Photopatch testing should be considered as an additional test, with the objective of differentiating between phototoxic and photoallergic reactions. As for laboratory findings, a positive anti-Ro/SSA titer should be considered a risk factor for drug-induced SLE<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a>. Furthermore, antihistone antibodies are detected in more than 95% of cases of drug-induced SLE, although they are also observed in 50%-70% of cases of SLE that are not drug-induced. In the case we report, the histone antibody test was negative, thus pointing us to a phototoxic reaction, as initially suspected.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In conclusion, we think that when assessing a patient with characteristics similar to those described here, the differential diagnosis should include drug-induced photosensitive rash, especially after initiation of treatment such as leflunomide, as in the present case. Additional tests, for example, patch (and photopatch) testing, are essential if we are to make an appropriate diagnosis.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0030" class="elsevierStylePara elsevierViewall">The authors declare that no funding was received for the present study.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflicts of Interest</span><p id="par0035" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Conflicts of Interest" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Navarro-Triviño FJ, Lucas-Collado N, Salvatierra-Ossorio J. Erupción fototóxica inducida por leflunomida en una paciente con lupus eritematoso sistémico. Actas Dermosifiliogr. 2021;112:939–941.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1711 "Ancho" => 758 "Tamanyo" => 186474 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A, Erythematous-violaceous maculopapular rash on the anterior trunk and neck. B, Erythematous-violaceous maculopapular rash on the posterior trunk with solitary bullous formations. C, Skin at 48 hours after onset of the rash, with formation of blisters.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1894 "Ancho" => 758 "Tamanyo" => 210624 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A, Erythematous, crusting rash with pustules on the forehead. B, Multiple vesicles on the area of the lips. C, Ecchymotic maculopapular rash on the axilla.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:7 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "T.W. Fischer" 1 => "H.I. Bauer" 2 => "T. Graefe" 3 => "U. Barta" 4 => "P. Elsner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000074120" "Revista" => array:6 [ "tituloSerie" => "Dermatology" "fecha" => "2003" "volumen" => "207" "paginaInicial" => "386" "paginaFinal" => "389" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14657632" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Leflunomide and Lyell syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.L. Schmutz" 1 => "A. Barbaud" 2 => "P. Tréchot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.annder.2008.12.021" "Revista" => array:5 [ "tituloSerie" => "Ann Dermatol Venereol" "fecha" => "2009" "volumen" => "136" "paginaInicial" => "395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19361717" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Leflunomide-induced DRESS syndrome with renal involvement and vasculitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "B. Pinto" 1 => "V. Dhir" 2 => "S. Krishnan" 3 => "R. Nada" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10067-012-2152-8" "Revista" => array:6 [ "tituloSerie" => "Clin Rheumatol" "fecha" => "2013" "volumen" => "32" "paginaInicial" => "689" "paginaFinal" => "693" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23271613" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Sues" 1 => "M. Sticherling" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-4632.2007.03333.x" "Revista" => array:6 [ "tituloSerie" => "Int J Dermatol" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "83" "paginaFinal" => "86" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18173611" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Leflunomide-induced ubacute cutaneous lupus erythematosus with erythema multiforme-like lesions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A.V. Marzano" 1 => "S. Ramoni" 2 => "N. Del Papa" 3 => "M. Barbareschi" 4 => "E. Alessi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/0961203307087189" "Revista" => array:6 [ "tituloSerie" => "Lupus" "fecha" => "2008" "volumen" => "17" "paginaInicial" => "329" "paginaFinal" => "331" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18413415" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Redefininf Rowell’s syndrome" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N.C. Zeitouni" 1 => "D. Funaro" 2 => "R.A. Cloutier" 3 => "E. Gagné" 4 => "L. Claveau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1365-2133.2000.03306.x" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2000" "volumen" => "142" "paginaInicial" => "343" "paginaFinal" => "346" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10730772" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Srivastave" 1 => "A. Rencic" 2 => "G. Diglio" 3 => "H. Santana" 4 => "P. Bonitz" 5 => "R. Watson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.139.1.45" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "2003" "volumen" => "139" "paginaInicial" => "45" "paginaFinal" => "49" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12533163" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011200000010/v1_202111080506/S1578219021002584/v1_202111080506/en/main.assets" "Apartado" => array:4 [ "identificador" => "6157" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case and Research Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011200000010/v1_202111080506/S1578219021002584/v1_202111080506/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002584?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 6 | 15 |
2024 October | 212 | 49 | 261 |
2024 September | 228 | 37 | 265 |
2024 August | 236 | 55 | 291 |
2024 July | 260 | 47 | 307 |
2024 June | 274 | 64 | 338 |
2024 May | 175 | 43 | 218 |
2024 April | 192 | 24 | 216 |
2024 March | 220 | 37 | 257 |
2024 February | 260 | 38 | 298 |
2024 January | 264 | 38 | 302 |
2023 December | 174 | 17 | 191 |
2023 November | 267 | 36 | 303 |
2023 October | 237 | 36 | 273 |
2023 September | 240 | 29 | 269 |
2023 August | 204 | 19 | 223 |
2023 July | 255 | 38 | 293 |
2023 June | 225 | 27 | 252 |
2023 May | 215 | 26 | 241 |
2023 April | 152 | 28 | 180 |
2023 March | 157 | 32 | 189 |
2023 February | 147 | 30 | 177 |
2023 January | 103 | 32 | 135 |
2022 December | 76 | 44 | 120 |
2022 November | 55 | 25 | 80 |
2022 October | 49 | 27 | 76 |
2022 September | 67 | 55 | 122 |
2022 August | 49 | 36 | 85 |
2022 July | 57 | 38 | 95 |
2022 June | 39 | 36 | 75 |
2022 May | 133 | 47 | 180 |
2022 April | 143 | 44 | 187 |
2022 March | 139 | 80 | 219 |
2022 February | 143 | 42 | 185 |
2022 January | 132 | 60 | 192 |
2021 December | 110 | 71 | 181 |
2021 November | 101 | 53 | 154 |
2021 October | 89 | 60 | 149 |